Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post‐metastatic liver biochip modeling

Abstract Two distinct genetic mutational pathways characterized by either chromosomal instability or high‐frequency microsatellite instability (MSI‐H) are recognized in the pathogenesis of colorectal cancer (CRC). Recently, it has been shown that patients with primary CRC that displays MSI‐H have a significant, stage‐independent, multivariate survival advantage. Biological properties of CMS1 (MSI‐H type) can affect therapeutic efficiencies of agents used in the treatment of CRC, and therefore become a new predictive factor of the treatment. But, the predictive impact of MSI‐H status for adjuvant chemotherapy remains controversial. This study will assess whether there is any unnecessary or inappropriate use of treatment agents recommended for adjuvant therapy of stage 2 and 3 of disease and for palliative or curative treatment of liver metastatic disease in microsatellite instability high group, a molecular subtype of colon cancer. Within this scope, the efficiencies of fluorouracil‐ and oxaliplatin‐based chemotherapeutic agents will be shown on stage 3 microsatellite instability high colon tumor cell lines first, and then a microfluidic model will be created, imitating the metastasis of colon cancer to the liver. In the microfluidic chip model, we will create in liver tissue, where the metastasis of microsatellite instability high colon cancer will be simulated; the effectiveness of chemotherapeutic agents, immunotherapy agents, and targeted agents on tumor cells as well as drug response will be assessed according to cell viability through released biomarkers from the cells. The proposed hypothesis study includes the modeling and treatment of patient‐derived post‐metastatic liver cancer in microfluidics which has priority at the global and our region and consequently develop personal medication.